logo
Share SHARE
FONT-SIZE Plus   Neg

Boehringer Ingelheim, Eli Lilly Submit NDA For Empagliflozin - Quick Facts

Boehringer Ingelheim and Eli Lilly and Company (LLY) announced that a New Drug Application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin was recently submitted to the FDA for the treatment of type 2 diabetes mellitus in adults.

Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Canada based Maple Leaf Foods Inc. Wednesday said it has reached a definitive agreement with Brynwood Partner VI L.P. for the acquisition of Lightlife Foods Inc. The deal would be worth $140 million plus other costs. Light is a brand in U.S. for refrigerated plant based protein foods. A hedge fund is an alternative investment fund that uses pooled funds from accredited individuals or institutional investors and invests these funds in different assets with a goal of generating high returns. Hedge funds are generally accessible only to accredited or qualified investors. They cannot... Off-price retailer TJX Companies, Inc. reported a nearly 2 percent increase in profit for the fourth quarter from last year, reflecting higher sales and customer traffic. Both revenue and earnings per share for the quarter beat analysts' expectations. The company forecast earnings for the first quarter below the Street estimates and projects fiscal 2018 earnings above their expectations.
comments powered by Disqus
Follow RTT